Inhibition of Acetylcholinesterase, β-Amyloid Aggregation, and NMDA Receptors in Alzheimer’s Disease: A Promising Direction for the Multi-target-Directed Ligands Gold Rush
Journal of Medicinal Chemistry2008Vol. 51(15), pp. 4381–4384
Citations Over TimeTop 10% of 2008 papers
Michela Rosini, Elena Simoni, Manuela Bartolini, Andrea Cavalli, Luisa Ceccarini, Nicoleta Elisabeta Pascu, David McClymont, Andrea Tarozzi, María Laura Bolognesi, Anna Minarini, Vincenzo Tumiatti, Vincenza Andrisano, Ian R. Mellor, Carlo Melchiorre
Abstract
Alzheimer's disease (AD) is a multifactorial syndrome with several target proteins contributing to its etiology. To confront AD, an innovative strategy is to design single chemical entities able to simultaneously modulate more than one target. Here, we present compounds that inhibit acetylcholinesterase and NMDA receptor activity. Furthermore, these compounds inhibit AChE-induced Abeta aggregation and display antioxidant properties, emerging as lead candidates for treating AD.
Related Papers
- → Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease(2001)157 cited
- → Role of Acetylcholinesterase in β-Amyloid Aggregation Studied by Accelerated Molecular Dynamics(2016)34 cited
- → Amyloid in Alzheimer’s Disease: Guilty Beyond Reasonable Doubt?(2017)24 cited
- → Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with β-amyloid peptides(2003)26 cited
- → Views on Amyloid Hypothesis and Secretase Inhibitors for Treating Alzheimers Disease: Progress and Problems(2006)36 cited